Search

Displaying results 2981 - 2990 of 10000 in total
  1. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). … Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.

  2. Drug

    Nemtabrutinib

    go.drugbank.com/drugs/DB18866
    Investigational

    trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK

  3. Drug

    Deracoxib

    go.drugbank.com/drugs/DB11395
    ExperimentalVet approved

    Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with orthopedic surgery in dogs.

  4. Drug

    Mercuric chloride

    go.drugbank.com/drugs/DB13765
    Experimental

    Mercury chloride (HgCl2) is a highly toxic compound that volatizes slightly at ordinary temperature and appreciably at 100 degrees C.

  5. Drug

    V591

    go.drugbank.com/drugs/DB16438
    Investigational

    Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593].

  6. Drug

    Telisotuzumab adizutecan

    go.drugbank.com/drugs/DB21832
    Investigational

    Telisotuzumab Adizutecan is under investigation in clinical trial NCT06614192 (A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and

  7. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.

  8. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. … [A261115] The loss of CD55 can therefore induce complement hyperactivation, causing the unwanted formation of membrane-attacking complex and resulting in paroxysmal nocturnal hemoglobinuria and complement-mediated

  9. Drug

    Polifeprosan 20

    go.drugbank.com/drugs/DB16298
    Investigational

    Polifeprosan 20 is under investigation in clinical trial NCT00003878 (Carmustine Implants in Treating Patients With Brain Metastases).

    Synonyms: Polifeprosan 20
  10. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of Streptococcus pneumoniae. It is an active immunization for intra...

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR